Protective effects of 4-phenylbutyrate derivatives on the neuronal cell death and endoplasmic reticulum stress

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 1, 2012, Pages 84-90

  Mimori, Seisuke ^a   Okuma, Yasunobu ^a   Kaneko, Masayuki ^a   Kawada, Koichi ^a   Hosoi, Toru ^b   Ozawa, Koichiro ^b   Nomura, Yasuyuki ^c   Hamana, Hiroshi ^a  

^a CHIBA INSTITUTE OF SCIENCE   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c YOKOHAMA COLLEGE OF PHARMACY   (Japan)

Author keywords

3 phenylpropionate; 4 phenylbutyrate; Endoplasmic reticulum stress

Indexed keywords

4 PHENYLBUTYRIC ACID; 5 PHENYLPENTANOIC ACID; 6 PHENYLHEXANOIC ACID; BOVINE SERUM ALBUMIN; FATTY ACID DERIVATIVE; GLUCOSE REGULATED PROTEIN 78; GLUCOSE REGULATED PROTEIN 94; HYDROCINNAMIC ACID; LACTALBUMIN; UNCLASSIFIED DRUG;

ARTICLE; BIOACCUMULATION; CELL MEMBRANE; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFECT; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; HUMAN; HUMAN CELL; IN VITRO STUDY; NERVE CELL NECROSIS; NEUROBLASTOMA CELL; NEUROPROTECTION; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; CARBON; CATTLE; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; ENDOPLASMIC RETICULUM STRESS; FATTY ACIDS, VOLATILE; HEAT-SHOCK PROTEINS; HUMANS; LACTALBUMIN; MEMBRANE GLYCOPROTEINS; NEUROBLASTOMA; NEURODEGENERATIVE DISEASES; NEURONS; NEUROPROTECTIVE AGENTS; NUCLEAR ENVELOPE; PHENYLBUTYRATES; PHENYLPROPIONATES; SERUM ALBUMIN; TUNICAMYCIN;

EID: 84855708250     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.84     Document Type: Article

References (29)

1. Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature, 417, 254-259 (2002).
2. Hammarström P, Wiseman RL, Powers ET, Kelly JW. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science, 299, 713-716 (2003).
3. May BC, Fafarman AT, Hong SB, Rogers M, Deady LW, Prusiner SB, Cohen FE. Potent inhibition of scrapie prion replication in cultured cells by bis-acridines. Proc. Natl. Acad. Sci. U.S.A., 100, 3416-3421 (2003).
4. Sánchez I, Mahlke C, Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature, 421, 373-379 (2003).
5. Klucken J, Shin Y, Hyman BT, McLean PJ. A single amino acid substitution differentiates Hsp70-dependent effects on alpha-synuclein degradation and toxicity. Biochem. Biophys. Res. Commun., 325, 367-373 (2004).
6. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 392, 605-608 (1998).
7. Imai Y, Soda M, Takahashi R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem., 275, 35661-35664 (2000).
8. Imai Y, Soda M, Inoue H, Hattori N, Mizuno Y, Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell, 105, 891-902 (2001).
9. Yang Y, Nishimura I, Imai Y, Takahashi R, Lu B. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron, 37, 911-924 (2003).
10. Kubota K, Niinuma Y, Kaneko M, Okuma Y, Sugai M, Omura T, Uesugi M, Uehara T, Hosoi T, Nomura Y. Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress. J. Neurochem., 97, 1259-1268 (2006).
11. Qi X, Hosoi T, Okuma Y, Kaneko M, Nomura Y. Sodium 4-phenylbutyrate protects against cerebral ischemic injury. Mol. Pharmacol., 66, 899-908 (2004).
12. Brusilow SW, Maestri NE. Urea cycle disorders: diagnosis, pathophysiology, and therapy. Adv. Pediatr., 43, 127-170 (1996).
13. Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW, Dover GJ. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood, 85, 43-49 (1995).
14. Mercuri E, Bertini E, Messina S, Pelliccioni M, D'Amico A, Colitto F, Mirabella M, Tiziano FD, Vitali T, Angelozzi C, Kinali M, Main M, Brahe C. Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul. Disord., 14, 130-135 (2004).
15. Carducci MA, Gilbert J, Bowling MK, Noe D, Eisenberger MA, Sinibaldi V, Zabelina Y, Chen TL, Grochow LB, Donehower RC. A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin. Cancer Res., 7, 3047-3055 (2001).
16. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, Görgün CZ, Hotamisligil GS. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science, 313, 1137-1140 (2006).
17. Tveten K, Holla ØL, Ranheim T, Berge KE, Leren TP, Kulseth MA. 4-Phenylbutyrate restores the functionality of a misfolded mutant low-density lipoprotein receptor. FEBS J., 274, 1881-1893 (2007).
18. Inden M, Kitamura Y, Takeuchi H, Yanagida T, Takata K, Kobayashi Y, Taniguchi T, Yoshimoto K, Kaneko M, Okuma Y, Taira T, Ariga H, Shimohama S. Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. J. Neurochem., 101, 1491-1504 (2007).
19. Ono K, Ikemoto M, Kawarabayashi T, Ikeda M, Nishinakagawa T, Hosokawa M, Shoji M, Takahashi M, Nakashima M. A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P+A53T transgenic mice. Parkinsonism Relat. Disord., 15, 649-654 (2009).
20. Ricobaraza A, Cuadrado-Tejedor M, Pérez-Mediavilla A, Frechilla D, Del Río J, García-Osta A. Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology, 34, 1721-1732 (2009).
21. Huang G, Li ZY, Zhou JM. Conformational specificity of trigger factor for the folding intermediates of alpha-lactalbumin. Biochim. Biophys. Acta, 1480, 77-82 (2000).
22. Kuwajima K. The molten globule state as a clue for understanding the folding and cooperativity of globular-protein structure. Proteins, 6, 87-103 (1989).
23. Li J, Zhang S, Wang C. Only the reduced conformer of alphalactalbumin is inducible to aggregation by protein aggregates. J. Biochem. (Tokyo), 129, 821-826 (2001).
24. Wang XZ, Harding HP, Zhang Y, Jolicoeur EM, Kuroda M, Ron D. Cloning of mammalian Ire1 reveals diversity in the ER stress responses. EMBO J., 17, 5708-5717 (1998).
25. Iwawaki T, Hosoda A, Okuda T, Kamigori Y, Nomura-Furuwatari C, Kimata Y, Tsuru A, Kohno K. Translational control by the ER transmembrane kinase/ribonuclease IRE1 under ER stress. Nat. Cell Biol., 3, 158-164 (2001).
26. Rubenstein RC, Egan ME, Zeitlin PL. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508- CFTR. J. Clin. Invest., 100, 2457-2465 (1997).
27. Ryu H, Lee J, Olofsson BA, Mwidau A, Deodoglu A, Escudero M, Flemington E, Azizkhan-Clifford J, Ferrante RJ, Ratan RR. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc. Natl. Acad. Sci. U.S.A., 100, 4281-4286 (2003).
28. Faraco G, Cavone L, Chiarugi A. The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis. Mol. Med., 17, 442-447 (2011).
29. Gardian G, Browne SE, Choi DK, Klivenyi P, Gregorio J, Kubilus JK, Ryu H, Langley B, Ratan RR, Ferrante RJ, Beal MF. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J. Biol. Chem., 280, 556-563 (2005).